Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688909 · ClinicalTrials.gov registry record · Phase 4
Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 261
- Enrollment target
NCT00688909 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 261 participants.
The verdict
NCT00688909, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 261 participants
- Enrollment target
Study Summary
This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole
Interventions
- DRUG letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00688909
The ClinicalTrials.gov registry entry for NCT00688909 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which letrozole is the first listed.
NCT00688909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00688909 about?
NCT00688909 is a clinical study titled "Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer". This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole
What is the current status of trial NCT00688909?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 261 participants. The study started on 2008-03. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00688909?
The interventions under investigation include: letrozole (DRUG).
Who is sponsoring clinical trial NCT00688909?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.